Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mometasone - EsoCap

Next Previous
X
Search
Drug Profile

Mometasone - EsoCap

Alternative Names: ESO 101; Mometasone furoate - EsoCap

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EsoCap AG
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis

Most Recent Events

  • 05 Dec 2023 Efficacy and adverse event data from the phase II ACESO trial in Eosinophilic oesophagitis released by EsoCap AG
  • 09 Oct 2023 EsoCap completes a phase-II trial in Eosinophilic oesophagitis (In adults, In the elderly) in Poland (PO) (NCT04849390)
  • 05 Sep 2023 EsoCap completes enrolment in its phase-II clinical trials in Eosinophilic oesophagitis in Poland (PO) (EudraCT2020-000082-16) (NCT04849390)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top